Posted by Michael Wonder on 12 Oct 2021
GenSight Biologics announces FDA grant of fast track designation for optogenetic therapy GS030 as treatment for retinitis pigmentosa
12 October 2021 - GenSight Biologics today announced that the U.S. FDA has granted fast track designation to GS030, which combines AAV2 based gene therapy with optogenetics to treat retinitis pigmentosa.
Optogenetic therapies combine cellular expression of light sensitive opsins with light stimulation using a medical device.
